Published in Cancer Weekly, August 4th, 2009
"The use of a proprietary enhancer system called GIPET(A ®), which is based on medium-chain fatty acids, facilitates the oral bioavailability of peptides. We hypothesized that GIPET(A ®) enhancement would allow for the safe oral dosing of acyline for the treatment of prostate cancer. We enrolled eight healthy young men in a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.